Abstract
A number of studies have identified a shared susceptibility locus in phospholipase C epsilon 1 (PLCE1) for esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinomas (GCA). However, the results of PLCE1 expression in esophageal and gastric cancer remain inconsistent and controversial. Moreover, the effects on clinicopathological features remain undetermined. This study aimed to provide a precise quantification of the association between PLCE1 expression and the risk of ESCC and GCA through meta-analysis. Eligible studies were identified from PubMed, Wanfang Data, ISI Web of Science, and the Chinese National Knowledge Infrastructure databases. Using RevMan5.2 software, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were employed to assess the association of PLCE1 expression with clinicopathological features relative to ESCC or GCA. Seven articles were identified, including 761 esophageal and gastric cancer cases and 457 controls. Overall, we determined that PLCE1 expression was associated with tumor progression in both esophageal cancers (pooled OR=5.93; 95%CI=3.86 to 9.11) and gastric cancers (pooled OR=9.73; 95%CI=6.46 to 14.7). Moreover, invasion depth (pooled OR=3.62; 95%CI=2.30 to 5.70) and lymph node metastasis (pooled OR=4.21; 95%CI=2.69 to 6.59) were linked with PLCE1 expression in gastric cancer. However, no significant associations were determined between PLCE1 overexpression and the histologic grade, invasion depth, and lymph node metastasis in esophageal cancer. Our meta- analysis results indicated that upregulated PLCE1 is significantly associated with an increased risk of tumor progression in ESCC and GCA. Therefore, PLCE1 expression can be appropriately regarded as a promising biomarker for ESCC and GCA patients.
Highlights
Cancer is the leading cause of death in both developed and developing countries
We determined that phospholipase C epsilon 1 (PLCE1) expression was associated with tumor progression in both esophageal cancers and gastric cancers
After assessing all eligible case-control studies involving 761 esophageal and gastric cancer cases and 457 controls, we determined that PLCE1 expression was associated with tumor progression in both esophageal and gastric cancers
Summary
Almost 12.7 million cancer cases and 7.6 million cancer deaths have recently been reported worldwide Among these cases, gastric and esophageal cancers are the most lethal malignancy and have caused 406,800 and 738,000 deaths, respectively (Jemal et al, 2011). Gastric and esophageal cancers are the most lethal malignancy and have caused 406,800 and 738,000 deaths, respectively (Jemal et al, 2011) The incidence of these two cancers varies considerably according to geographic locations and ethnicity. This study aimed to provide a precise quantification of the association between PLCE1 expression and the risk of ESCC and GCA through meta-analysis. Conclusions: Our metaanalysis results indicated that upregulated PLCE1 is significantly associated with an increased risk of tumor progression in ESCC and GCA. PLCE1 expression can be appropriately regarded as a promising biomarker for ESCC and GCA patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
